- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dana-Farber Cancer Institute | Strategic Alliance Partners
Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.
Latest from Dana-Farber Cancer Institute
Dr Winer on the Rationale for the TakeAim Leukemia Trial in Mutated AML
June 21, 2024
Video
Eric Winer, MD, discusses the rationale for the phase 1/2a TakeAim Leukemia trial of emavusertib in patients with R/R FLT3- and spliceosome-mutated AML.
Dr Tarantino on Updated Survival Data With T-DXd in HER2+ Breast Cancer
June 19, 2024
Video
Paolo Tarantino, MD, discusses updated data from the phase 3 DESTINY-Breast03 trial of trastuzumab deruxtecan in HER2-positive breast cancer.
Emavusertib Monotherapy Shows Antitumor Activity, Safety in Select R/R AML and High-Risk MDS
June 19, 2024
Article
Emavusertib monotherapy was tolerable and produced responses in patients with FLT3-mutant relapsed/refractory acute myeloid leukemia.
Dana-Farber Researchers Uncover Disparities in Lived Experiences for Patients and Physicians
June 19, 2024
Article
Dana-Farber Cancer Institute investigators have found that people experience discrimination in different ways and in various realms of cancer care.
Dr Bellmunt on Predictive Signatures for Checkpoint Inhibitor Responses in Urothelial Cancer
June 11, 2024
Video
Joaquim Bellmunt, MD, PhD, discusses the predictive value of H3K27ac epigenomic and single-cell transcriptional profiling in urothelial cancer.
Dr Nayak on the Investigation of Axi-Cel in CNS Lymphoma
June 11, 2024
Video
Lakshmi Nayak, MD, discusses the investigation of axi-cel in patients with relapsed/refractory primary and secondary CNS lymphoma.
Axi-Cel Shows Safety, Clinical Activity in R/R Primary and Secondary CNS Lymphomas
June 11, 2024
Article
Axi-cel administration was safe and clinically active in relapsed/refractory primary and secondary central nervous system lymphoma.
Enhancing the Referral Process for Genetic Testing Represents Key Next Step in Breast Cancer
June 11, 2024
Article
Brittany Bychkovsky, MD, MSc, discusses the role of genetic testing in breast cancer care and explores approaches to improving the testing process.
Most Young Breast Cancer Survivors Can Have Children
June 07, 2024
Article
Most young breast cancer survivors can go on to have children despite the effects of their lifesaving treatment, a new study shows.
Dr Garrido-Castro on Sacituzumab Govitecan With or Without Pembrolizumab in Metastatic HR+/HER2– Breast Cancer
June 05, 2024
Video
Ana Christina Garrido-Castro, MD, on sacituzumab govitecan with/without pembrolizumab in metastatic hormone receptor–positive, HER2-negative breast cancer.
Dr McGregor on the Rationale for the DAD Trial in Metastatic Urothelial Cancer
June 04, 2024
Video
Bradley McGregor, MD, discusses the investigation of sacituzumab govitecan plus enfortumab vedotin in metastatic urothelial cancer.
Dr McGregor on the DAD-IO Trial in Treatment-Naive Metastatic Urothelial Carcinoma
June 04, 2024
Video
Bradley McGregor, MD, discusses the DAD-IO trial of sacituzumab govitecan, enfortumab vedotin, and pembrolizumab in metastatic urothelial cancer.
Dr Park on the Combo of Epacadostat and Chemoradiation in Advanced Rectal Cancer
May 30, 2024
Video
Haeseong Park, MD, MPH, discusses the rationale for combining epacadostat with preoperative chemoradiation in locally advanced rectal cancer.
Non-Pharmacologic Therapies for Pain Management in Patients With Cancer: Opportunities and Challenges
May 27, 2024
Article
Janet Abrahm, MD, FACP, FAAHPM, reviews the standing of the role of integrative therapies in cancer care.
Exploiting the Vulnerabilities of High-Grade Serous Ovarian Cancer Through WEE1 Inhibition
May 23, 2024
Article
Joyce F. Liu, MD, MPH, provides insights on WEE1 which has emerged as a potentially targetable pathway in high-grade serous ovarian cancer.
Cancer Vaccines Approach New Horizons in Melanoma and Other Solid Tumors
May 22, 2024
Article
Patrick Ott, MD, PhD, discusses the investigation of cancer vaccines, highlighting the clinical implications of this treatment modality in melanoma.
Addressing Research Into the Association Between Tumor Mutations and Responses in RCC
May 21, 2024
Article
Eliezer Van Allen, MD, discusses immuno-oncology in relation to precision cancer medicine.
Epacadostat Plus Preoperative Chemoradiation Is Feasible in Locally Advanced Rectal Cancer
May 21, 2024
Article
Haeseong Park, MD, MPH, discusses findings from a phase 1 study of epacadostat with preoperative chemoradiation in locally advanced rectal cancer.
Mirvetuximab Soravtansine Plus Pembrolizumab Generates Reponses in pMMR FRα+ Serous Endometrial Cancer
May 20, 2024
Article
Rebecca Porter, MD, PhD, discusses mirvetuximab soravtansine plus pembrolizumab in serous endometrial cancer and future directions for ADCs in the space.
Dr Liu on the Rationale for Targeting Wee1 in Ovarian Cancer
May 13, 2024
Video
Joyce F. Liu, MD, MPH, discusses the role of Wee1 in cell cycle regulation and the rationale for targeting this protein in ovarian cancer.